PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

PTC Therapeutics (NASDAQ: PTCT) announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026 at 9:00 a.m. PST / 12:00 p.m. EST.

The presentation will be webcast live on the company’s Events and Presentations investor page at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.

Key Figures

Conference edition 44th Annual J.P. Morgan Healthcare Conference

Presentation date Jan. 12, 2026 Scheduled CEO presentation time

Presentation time PST 9 a.m. PST J.P. Morgan Healthcare Conference slot

Presentation time EST 12 p.m. EST J.P. Morgan Healthcare Conference slot

Webcast archive period 30 days Investor replay availability after presentation

Market Reality Check

$76.85 Last Close

Volume Volume 879,300 vs 20-day average 2,249,164 (relative volume 0.39x). low

Technical Trading above 200-day MA of 56.33 with price at 74.94, indicating an established uptrend pre-announcement.

Peers on Argus

PTCT was down 0.64% while close biotech peers showed mixed, mostly small moves: RNA -0.06%, CRSP -1.79%, MRUS -0.06%, KRYS -0.82%, and TGTX +1.87%. This points to stock-specific rather than broad sector-driven action around the conference news.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Inducement grants	Neutral	-7.9%	New-hire inducement equity grants with options and RSUs under Nasdaq Rule 5635(c)(4).
Nov 20	R&D day announcement	Positive	+1.1%	Scheduled R&D Day to showcase small molecule splicing and inflammation platforms.
Nov 04	Q3 2025 earnings	Positive	-0.3%	Reported Q3 2025 revenue, positive net income and updated full-year guidance.
Oct 31	Investor conferences	Neutral	+0.3%	Participation in multiple global healthcare investor conferences with webcasts.
Oct 27	Inducement grants	Neutral	+0.6%	Inducement equity awards for new employees with four-year vesting terms.

Pattern Detected

Recent headlines (earnings, R&D and conference participation, inducement grants) have generally produced modest single-day moves, with one larger decline following an inducement grant announcement.

Recent Company History

Over the last few months, PTC Therapeutics reported Q3 2025 results with $211.0M revenue and positive net income of $15.9M, alongside narrowed 2025 revenue guidance. The company highlighted launches and regulatory milestones for Sephience and other products. It has also frequently announced inducement equity grants and participation in multiple healthcare investor conferences. Today’s J.P. Morgan Healthcare Conference appearance continues this pattern of regular investor-focused communication and non-clinical corporate updates.

Market Pulse Summary

This announcement schedules a CEO presentation at the 44th J.P. Morgan Healthcare Conference, extending PTC Therapeutics’ pattern of active participation in investor events. It follows recent Q3 2025 results with revenue of $211.0M and positive net income of $15.9M, plus multiple conference and R&D updates. Investors may track any new strategic or pipeline commentary from the presentation and relate it to prior guidance, recent regulatory milestones, and ongoing insider trading activity disclosed in recent Form 4 filings.

AI-generated analysis. Not financial advice.

WARREN, N.J., Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44^th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 9 a.m. PST/12 p.m. EST.

The presentation will be webcast live on the Events and Presentations page of the Investors section of the PTC Therapeutics website at https://ir.ptcbio.com/events-presentations, and it will be archived for 30 days following the presentation.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook, and Instagram.

For More Information:

Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302645455.html

SOURCE PTC Therapeutics, Inc.

FAQ

When will PTC Therapeutics (PTCT) present at the J.P. Morgan Healthcare Conference?

PTC CEO will present on Monday, Jan. 12, 2026 at 9:00 a.m. PST / 12:00 p.m. EST.

How can investors watch the PTCT presentation at J.P. Morgan 2026?

The presentation will be webcast live on the company Events and Presentations investor page at https://ir.ptcbio.com/events-presentations.

Will the PTCT J.P. Morgan presentation be available after the live event?

Yes, the webcast will be archived for 30 days following the presentation.

Who from PTC Therapeutics will present at the J.P. Morgan Healthcare Conference?

CEO Matthew B. Klein, M.D. is scheduled to present.

What time is the PTCT presentation in Eastern Time on Jan. 12, 2026?

The presentation is at 12:00 p.m. Eastern Time on Jan. 12, 2026.

Where on the PTC Therapeutics website is the J.P. Morgan webcast hosted?

The webcast is hosted on the company’s Events and Presentations page in the Investors section: https://ir.ptcbio.com/events-presentations.